SEC Form 10-Q Summary
Filing identity: The supplied filing is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarterly period ended September 30, 2012, with unaudited financial statements for the three and nine months ended September 30, 2012 and comparable 2011 periods.
Business Context and Reporting Period
Neuralstem was a development-stage biotechnology company focused on human neuronal stem-cell therapies and small-molecule compounds for central nervous system diseases. Its principal programs included ALS, chronic spinal cord injury, ischemic stroke and NSI-189 for major depressive disorder.
- The Phase I ALS trial was completed in August 2012 after treating 18 patients. Management anticipated starting a Phase II ALS trial in the first half of 2013.
- In September 2012, the company received approval to begin a combined Phase I/II ischemic-stroke trial in China, expected to begin in early 2013 and designed to enroll up to 118 patients.
- The NSI-189 Phase Ib trial had dosed eight of an anticipated 24 major-depressive-disorder patients as of the filing.
- The initial year of the Department of Defense subcontract was completed in the second quarter of 2012, and continuation was uncertain because of budget constraints.
Financial Metrics
| Metric | Three months ended September 30, 2012 | Three months ended September 30, 2011 | Nine months ended September 30, 2012 | Nine months ended September 30, 2011 |
|---|---|---|---|---|
| Revenue | $170,833 | $103,417 | $405,208 | $103,417 |
| Operating expenses | $2,753,992 | $3,326,484 | $7,834,838 | $10,531,854 |
| Operating loss | $(2,583,159) | $(3,223,067) | $(7,429,630) | $(10,428,437) |
| Net loss | $(2,577,391) | $(3,211,604) | $(7,406,553) | $(9,962,131) |
| Net loss per share | $(0.04) | $(0.07) | $(0.14) | $(0.21) |
| Net cash used in operating activities | Not provided for the quarter | Not provided for the quarter | $(5,959,436) | $(6,314,028) |
- Approximate operating margin was negative 1,512% in the third quarter and negative 1,833% for the first nine months. Approximate net margin was negative 1,509% and negative 1,828%, respectively.
- Cash and cash equivalents were $9.87 million at September 30, 2012, compared with $2.35 million at December 31, 2011 and $4.20 million at September 30, 2011.
- Total assets were $11.24 million and total liabilities were $2.14 million at September 30, 2012. Stockholders’ equity was $9.10 million.
- Current liabilities were $2.12 million, including $1.50 million of accounts payable and accrued expenses and $479,368 of accrued bonus expense. The filing does not present a material long-term debt balance; a $146,452 insurance-premium note was disclosed as a noncash financing activity, with $16,272 of payments during the first nine months.
- Net cash provided by financing activities was $13.67 million, primarily from equity offerings. Investing cash use was $188,318, including patent filing fees and property purchases.
- Share-based compensation expense was $1.19 million for the first nine months of 2012, down from $2.87 million in the comparable 2011 period.
Material Changes Versus the Prior Comparable Period
- Third-quarter revenue increased to $170,833 from $103,417, primarily because of approximately $170,000 of intellectual-property licensing revenue. There were no product sales.
- Nine-month revenue increased to $405,208 from $103,417. The 2012 amount included approximately $234,000 from the Department of Defense subcontract and $170,000 from intellectual-property licensing.
- Third-quarter research and development expense declined 35% to $1.39 million, primarily because certain studies ended in 2011 and stock-based compensation decreased.
- Nine-month research and development expense declined 26% to $4.41 million, while general and administrative expense declined 26% to $3.26 million. The reductions reflected lower stock compensation, legal expenses, bonuses and salaries.
- Nine-month net loss improved by approximately $2.56 million, although the 2011 period benefited from a $250,000 litigation settlement and a $161,809 warrant fair-value gain that did not recur in 2012.
- The company raised approximately $15 million gross during the first nine months through common-stock and warrant offerings. Outstanding common shares increased to 67.96 million at September 30, 2012, from 48.68 million at December 31, 2011, creating significant dilution risk.
Guidance, Outlook, Risks and Unusual Items
- Management estimated monthly operating cash burn at approximately $700,000 and expected available cash, expected income and expected financing proceeds to fund current activities at least through September 30, 2013, although activities and personnel might need to be reduced.
- The company did not expect to become profitable in the next several years and stated that substantial additional capital would be required for research, clinical trials, regulatory approvals, manufacturing and general operations.
- Approximately $28.8 million remained available under the company’s $50 million shelf registration statement, but future financing was dependent on market conditions and development progress and was not assured.
- Major risks included clinical-trial failure, regulatory delays or denial, dependence on third-party manufacturers and clinical-service providers, intellectual-property challenges, need for additional financing, dilution from future equity issuances and limited commercial revenue.
- The chronic spinal-cord-injury IND remained on clinical hold, and the timing of any resumption was uncertain.
- Patent litigation with StemCells, Inc. remained pending. The court had stayed other matters while addressing standing and related discovery; management could not predict the outcome or timing.
- Management reported that disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.
Investor Verification Checklist
- Verify the issuer name and filing accession details because the supplied request identifies Palisade Bio, while the filing text identifies Neuralstem, Inc.
- Confirm cash runway assumptions against the approximately $700,000 monthly operating cash burn and the company’s need for future financing.
- Review the terms, exercise prices and potential dilution from the substantial outstanding options, warrants and reserved shares.
- Assess the clinical and regulatory status of the ALS, ischemic-stroke, NSI-189 and spinal-cord-injury programs, including the spinal-cord-injury clinical hold.
- Review the status and potential financial impact of the StemCells patent litigation and any related intellectual-property rights.
- Determine whether licensing revenue is recurring or largely nonrecurring and confirm the status of the discontinued or uncertain Department of Defense program.